04 Nov 2026
Disruptive Pharma strengthens R&D team with Rosita Pettersson Kneiszl
Disruptive Pharma continues to grow its team with the addition of Rosita Pettersson Kneiszl as Formulation Scientist, strengthening our formulation development capabilities as we advance Formulite® and expand our work with pharmaceutical and biotechnology partners.
Read More
22 Sep 2026
Disruptive Pharma divests GTX platform and retains rights to future royalty and milestone revenues
Disruptive Pharma AB (publ) ("Disruptive Pharma" or the "Company") today announced that it has entered into an agreement to sell the GTX platform to a wholly owned subsidiary of Aurelia Invest AB ("Aurelia"). The transaction is the result of the process initiated in June 2026 to evaluate strategic alternatives for the GTX platform, which was deemed to fall outside the business focus that Disruptive Pharma intends to pursue following the reverse takeover of Disruptive Pharma Holding AB.
Read More